Core Viewpoint - TC BioPharm (Holdings) PLC has been notified of its delisting from Nasdaq due to non-compliance with the minimum bid price requirement of $1.00 per share, and the company is currently appealing this decision [1][2]. Company Overview - TC BioPharm is a clinical-stage biotechnology company focused on developing allogeneic gamma-delta T cell therapies for cancer treatment, with a specific emphasis on acute myeloid leukemia [4][5]. - The company is recognized as a leader in the development of gamma-delta T cell therapies and is the first to conduct phase II/pivotal clinical studies in oncology [5]. Current Developments - Trading of the company's securities will be suspended on Nasdaq starting March 24, 2025, but its American Depositary Shares are expected to be eligible for trading on the OTC Markets from the same date [2]. - Despite the delisting, TC BioPharm remains committed to advancing its research, clinical trials, and therapeutic development initiatives [3].